Literature DB >> 2949788

Pharmacoclinical data on high dose medroxyprogesterone acetate in advanced breast cancer.

M Namer, G Milano, R Khater, M Frenay, A Thyss, N Renée.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2949788     DOI： 10.1007/bf01807705

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


× No keyword cloud information.
  7 in total

1.  Determination of medroxyprogesterone acetate in plasma by high-performance liquid chromatography.

Authors:  G Milano; G Carle; N Renée; J L Boublil; M Namer
Journal:  J Chromatogr       Date:  1982-11-12

2.  Evaluation of estrogen receptor assays in human breast cancer tissue.

Authors:  W L McGuire; M De La Garza; G C Chamness
Journal:  Cancer Res       Date:  1977-03       Impact factor: 12.701

3.  Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients.

Authors:  H van Veelen; P H Willemse; D T Sleijfer; E van der Ploeg; W J Sluiter; H Doorenbos
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer.

Authors:  D W Hedley; M Christie; R P Weatherby; I D Caterson
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology.

Authors:  V Tamassia; A Battaglia; F Ganzina; A M Isetta; G Sacchetti; F Cavalli; A Goldhirsch; K Brunner; G Bernardo; G Robustelli della Cuna
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  Simultaneous micro measurement of steroid receptors in breast cancer.

Authors:  G Milano; J L Moll; J L Formento; M Francoual; B P Krebs; M Namer; J L Boublil; C M Lalanne
Journal:  Br J Cancer       Date:  1983-10       Impact factor: 7.640

7.  An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.

Authors:  J R Johnson; T J Priestman; K Fotherby; K A Kelly; S G Priestman
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.